This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the rate of response in the American College of Rheumatology 20 response rate (ACR 20) at 6 months; the rate of withdrawals at each 6-month period; the initial Health Assessment Questionnaire (HAQ) improvement; the 6-monthly HAQ progression on treatment; the change in utility score; and mortality.
Study designs and other criteria for inclusion in the review
A formal review of the literature was not performed. The evidence on etanercept was derived from a Phase III randomised clinical trial (RCT). Results of meta-analyses, RCTs, or observational studies were used for other model inputs. Personal communications were also used.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The bulk of the evidence used in the model was derived from 18 primary studies.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The rate of response in the ACR 20 at 6 months was 50% with etanercept, 37% with intramuscular gold (DMARD A), 37% with leflunomide (DMARD B) and 48% with cyclosporin (DMARD C).
The rate of withdrawals at each 6-month period was 4.04% with etanercept, 10.6% with DMARD A, 20.66% with DMARD B and 25.30% with DMARD C.
The initial HAQ improvement was -0.8421 with etanercept, -0.43 with DMARD A, -0.524 with DMARD B and -0.3531 with DMARD C.
The 6-monthly HAQ progression on treatment was 0.0075 with etanercept, and 0.017 with DMARD A, DMARD B and DMARD C.
